On July30, 2018, SteadyMed Ltd. (the “Company”) held an extraordinary general meeting of its shareholders (the “Meeting”). The required quorum was present. The following is a summary of the proposals and the voting results from the Meeting. A complete description of each matter is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on June25, 2018, as supplemented by the definitive additional materials filed with the Securities and Exchange Commission on June29, 2018 and July16, 2018 (together, the “Proxy Statement”).